Cargando…

Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies

INTRODUCTION: This integrated phase 3 analysis examined efficacy and cardiovascular safety for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients. METHODS: Efficacy and safety results from four phase 3, randomized, open-label studies comparing roxadustat to ESAs (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barratt, Jonathan, Sulowicz, Wladyslaw, Schömig, Michael, Esposito, Ciro, Reusch, Michael, Young, James, Csiky, Botond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478753/ https://www.ncbi.nlm.nih.gov/pubmed/34523074 http://dx.doi.org/10.1007/s12325-021-01903-7

Ejemplares similares

Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)
por: Csiky, Botond, et al.
Publicado: (2021)

Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)
por: Shutov, Evgeny, et al.
Publicado: (2021)

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
por: Barratt, Jonathan, et al.
Publicado: (2023)

Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)
por: Barratt, Jonathan, et al.
Publicado: (2021)

Erratum to: Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomised, open-label, active-controlled study (DOLOMITES)
por: Barratt, Jonathan, et al.
Publicado: (2022)

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
por: Provenzano, Robert, et al.
Publicado: (2020)

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
por: Akizawa, Tadao, et al.
Publicado: (2021)

Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study
por: Akizawa, Tadao, et al.
Publicado: (2019)

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
por: Akizawa, Tadao, et al.
Publicado: (2019)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Retraction notice to “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.” Kidney Int Rep. 2021;6:613–623
por: Provenzano, Robert, et al.
Publicado: (2022)

Comparison of the incidence of skin cancers in patients on dialysis and after kidney transplantation
por: Sułowicz, Joanna, et al.
Publicado: (2017)

Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies
por: Topf, Joel, et al.
Publicado: (2022)

Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin
por: Sepah, Yasir J., et al.
Publicado: (2022)

Roxadustat for CKD-related Anemia in Non-dialysis Patients
por: Coyne, Daniel W., et al.
Publicado: (2020)

Population pharmacokinetics of roxadustat in Japanese dialysis‐dependent chronic kidney disease patients with anaemia
por: Takada, Akitsugu, et al.
Publicado: (2021)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
por: Zhou, Qiaoqiao, et al.
Publicado: (2023)

Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia
por: Zhu, Xin-Wang, et al.
Publicado: (2021)

Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies
por: Akizawa, Tadao, et al.
Publicado: (2020)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
por: Hirai, Keiji, et al.
Publicado: (2023)

Safety and Effectiveness of Roxadustat in Dialysis-Dependent Patients With Renal Anemia: A Hospital-Based Cohort Study
por: Moussa, Oumarou, et al.
Publicado: (2022)

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
por: Hirai, Keiji, et al.
Publicado: (2021)

Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
por: Zhang, Yangyang, et al.
Publicado: (2023)

Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
por: Grzeszczak, Władysław, et al.
Publicado: (2021)

Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
por: Groenendaal-van de Meent, Dorien, et al.
Publicado: (2020)

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
por: Wu, Tong, et al.
Publicado: (2022)

The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Wang, Lijun, et al.
Publicado: (2022)

The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials
por: Abdelazeem, Basel, et al.
Publicado: (2022)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

The role of roxadustat in chronic kidney disease patients complicated with anemia
por: Liu, Jie, et al.
Publicado: (2023)

Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis
por: Yang, Zhikai, et al.
Publicado: (2021)

Short-term effects of roxadustat on serum copper and iron changes in a peritoneal dialysis patient
por: Nakamura, Hironori, et al.
Publicado: (2022)

Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials
por: Chen, Ting, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
por: Czock, David, et al.
Publicado: (2021)

A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study
por: Charytan, Chaim, et al.
Publicado: (2021)

Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study
por: Zhang, Xuejie, et al.
Publicado: (2023)

The efficacy of Roxadustat for the treatment of anemia in dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials
por: Abdelazeem, Basel, et al.
Publicado: (2021)

Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat
por: Akizawa, Tadao, et al.
Publicado: (2022)

Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
por: Liu, Chao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1a9ruoaocfgf0jrr4qo3i24vlk